BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023
30 nov. 2023 07h00 HE
|
BioXcel Therapeutics
Company to review BXCL502 and other potential emerging pipeline candidates Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer’s disease and BXCL502 as a potential treatment Dr. Sandra...
BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
14 nov. 2023 07h00 HE
|
BioXcel Therapeutics
Company plans to conduct Phase 3 trial of BXCL501 in the at-home setting for TRANQUILITY program to support potential sNDA for acute treatment of agitation associated with dementia due to probable...
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype
08 nov. 2023 07h00 HE
|
BioXcel Therapeutics
Median overall survival of 15.5 months with BXCL701 + KEYTRUDA® (pembrolizumab), compared to 9.6 months with checkpoint inhibitor monotherapy in late-line refractory patients in separate Phase 2...
BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)
06 nov. 2023 07h00 HE
|
BioXcel Therapeutics
Columbia University-led trial expected to add fourth site to target completion of 4-arm, 160-patient trial in 2024 Fentanyl adulterated or associated with xylazine (FAAX) designated an emerging...
BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023
31 oct. 2023 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in...
BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services
30 oct. 2023 07h00 HE
|
BioXcel Therapeutics
Standardizes and improves product reimbursement process New HCPCS Level II code J1105 to be effective January 1, 2024 NEW HAVEN, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc....
BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site
25 oct. 2023 07h00 HE
|
BioXcel Therapeutics
No evidence of misconduct or fraud found beyond instance previously reported1 No findings identified that impact data integrity Company believes audit findings support reliability of positive...
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer
10 oct. 2023 07h00 HE
|
BioXcel Therapeutics
Median overall survival of 13.6 months with BXCL701 + KEYTRUDA® (pembrolizumab), compared to 7.6 months with checkpoint inhibitor monotherapy (CPI) in late-line refractory patients in separate, Phase...
BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film
04 oct. 2023 07h00 HE
|
BioXcel Therapeutics
Meetings scheduled with FDA in October and November for TRANQUILITY and SERENITY III programs Company strengthens IGALMI™ market exclusivity through receipt of two Notices of Allowance ...
BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization
14 août 2023 07h00 HE
|
BioXcel Therapeutics
Business to prioritize high-potential agitation market opportunities for BXCL501 in bipolar disorders, schizophrenia, and Alzheimer’s disease Commercial reprioritization intended to reduce related...